COSTA MESA, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today presented its 48-week data from the Infergen® (Consensus Interferon) DIRECT trial at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston. Dr. Bruce Bacon, the DIRECT trial lead investigator and Director of the Division of Gastroenterology and Hepatology at Saint Louis University, presented the data in the late-breaker poster session.
